8 September 2023

Braveheart Investment Group plc

("Braveheart" or the "Group")

 Investment update - Kirkstall Limited

Braveheart Investment Group (AIM: BRH), announces an update on Kirkstall Limited ("Kirkstall" or the "Company"), a company within the Group's investment portfolio.

Kirkstall, in conjunction with the Biomedical Ultrasonics, Biotherapy and Biopharmaceutical Laboratory within the Institute of Biomedical Engineering at the University of Oxford, has developed an "organ on a chip" model of an innovative, milli-fluidic system, human blood-brain barrier which has been used to map the interaction between the blood-brain barrier and brain cancer.

This is the first time a dynamic milli-fluidic model has been developed where the interactions between the blood-brain barrier and medulloblastoma brain cancer spheroids have been demonstrated. The model uses the Kirkstall's Quasi Vivo® platform, a unique milli-fluidic system. This innovation will enable the observation of the in vitro performance of drugs designed for treating brain cancer and central nervous system diseases such as Alzheimer's.

Braveheart holds a 86.11% equity interest in Kirkstall. In addition, it has provided unsecured interest free loans to Kirkstall totalling £10,752 as at 31 March 2023.

Trevor Brown, CEO of Braveheart Investment Group plc, commented: "It is exciting to observe how collaboration between Kirkstall and Oxford University has resulted in an innovative and important application for the Quasi Vivo platform."

For further information: